Ola E. Dahl

8.3k total citations · 3 hit papers
85 papers, 6.3k citations indexed

About

Ola E. Dahl is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Ola E. Dahl has authored 85 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Internal Medicine, 72 papers in Cardiology and Cardiovascular Medicine and 24 papers in Surgery. Recurrent topics in Ola E. Dahl's work include Venous Thromboembolism Diagnosis and Management (73 papers), Atrial Fibrillation Management and Outcomes (52 papers) and Acute Myocardial Infarction Research (28 papers). Ola E. Dahl is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (73 papers), Atrial Fibrillation Management and Outcomes (52 papers) and Acute Myocardial Infarction Research (28 papers). Ola E. Dahl collaborates with scholars based in Norway, United Kingdom and Germany. Ola E. Dahl's co-authors include Bengt I. Eriksson, Sylvia Haas, Sam Schulman, Frank Misselwitz, Ajay K. Kakkar, Clifford W. Colwell, Charles W. Francis, Catherine Curley, Thomas L. Ortel and Stephen G. Pauker and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Ola E. Dahl

82 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention of VTE in Orthopedic Surgery Patients

2012 1.4k citations Ola E. Dahl et al. profile →
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

2007 812 citations Bengt I. Eriksson, Ola E. Dahl et al. The Lancet profile →
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

2008 807 citations Ajay K. Kakkar, Benjamin Brenner et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ola E. Dahl Norway	28	5.1k	4.6k	2.1k	688	602	85	6.3k
Lars C. Borris Denmark	27	3.7k 0.7×	3.4k 0.7×	1.5k 0.7×	568 0.8×	375 0.6×	104	4.8k
Nadia Rosencher France	31	4.5k 0.9×	4.3k 0.9×	1.9k 0.9×	741 1.1×	412 0.7×	107	6.2k
Frank Misselwitz Germany	33	6.9k 1.4×	7.8k 1.7×	1.7k 0.8×	1.1k 1.7×	514 0.9×	96	9.2k
Patrick Mismetti France	31	5.2k 1.0×	4.6k 1.0×	1.8k 0.9×	1.1k 1.6×	403 0.7×	118	6.8k
Bruce L. Davidson United States	30	5.5k 1.1×	5.2k 1.1×	1.4k 0.7×	915 1.3×	973 1.6×	53	6.9k
Sylvia Haas Germany	43	6.4k 1.3×	7.2k 1.6×	1.8k 0.9×	1.2k 1.7×	520 0.9×	209	9.1k
Alexander G.G. Turpie Canada	40	5.8k 1.1×	6.8k 1.5×	2.6k 1.2×	812 1.2×	567 0.9×	114	8.7k
Alexander G.G. Turpie Canada	33	5.2k 1.0×	4.0k 0.9×	1.7k 0.8×	918 1.3×	426 0.7×	89	6.0k
Alexander T. Cohen United Kingdom	19	4.8k 1.0×	3.7k 0.8×	1.2k 0.6×	788 1.1×	284 0.5×	44	5.3k
Geno J. Merli United States	37	4.8k 0.9×	3.8k 0.8×	1.7k 0.8×	723 1.1×	369 0.6×	155	6.3k

Countries citing papers authored by Ola E. Dahl

Since Specialization

Citations

This map shows the geographic impact of Ola E. Dahl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola E. Dahl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola E. Dahl more than expected).

Fields of papers citing papers by Ola E. Dahl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ola E. Dahl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola E. Dahl. The network helps show where Ola E. Dahl may publish in the future.

Co-authorship network of co-authors of Ola E. Dahl

This figure shows the co-authorship network connecting the top 25 collaborators of Ola E. Dahl. A scholar is included among the top collaborators of Ola E. Dahl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ola E. Dahl. Ola E. Dahl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dybvik, Eva, et al.. (2020). Do direct oral anticoagulants (DOACs) cause delayed surgery, longer length of hospital stay, and poorer outcome for hip fracture patients?. European Geriatric Medicine. 11(4). 563–569. 28 indexed citations

Jeske, Walter, et al.. (2019). Urinary Prothrombin Fragment 1 + 2 as an Endogenous Marker of Venous Thromboembolism. 4(2). 1 indexed citations

Dahl, Ola E., et al.. (2012). Blood Loss in Cemented THA is not Reduced with Postoperative Versus Preoperative Start of Thromboprophylaxis. Clinical Orthopaedics and Related Research. 470(9). 2591–2598. 10 indexed citations

Eriksson, Bengt I., Ola E. Dahl, Martin Feuring, et al.. (2012). Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: A pooled analysis. Thrombosis Research. 130(5). 818–820. 17 indexed citations

Talsnes, Ove, et al.. (2012). Biochemical lung, liver and kidney markers and early death among elderly following hip fracture. Archives of Orthopaedic and Trauma Surgery. 132(12). 1753–1758. 13 indexed citations

Marx, Svetlana, Ola E. Dahl, Victor J. Marder, et al.. (2012). Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thrombosis and Haemostasis. 108(11). 903–912. 18 indexed citations

Kakkar, Ajay K., Benjamin Brenner, Ola E. Dahl, et al.. (2008). Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. The Lancet. 372(9632). 31–39. 807 indexed citations breakdown →

Eriksson, Bengt I., Kenneth A. Bauer, Lars C. Borris, et al.. (2007). Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies. Thrombosis and Haemostasis. 97(6). 931–937. 56 indexed citations

Dahl, Ola E., Mats Ögren, Giancarlo Agnelli, et al.. (2006). Assessment of Bleeding after Concomitant Administration of Antiplatelet and Anticoagulant Agents in Lower Limb Arthroplasty. Pathophysiology of Haemostasis and Thrombosis. 35(6). 428–434. 5 indexed citations

10.

Dahl, Ola E., Bengt I. Eriksson, Giancarlo Agnelli, et al.. (2005). Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery. Clinical Drug Investigation. 25(1). 65–77. 10 indexed citations

11.

Stangier, Joachim, Bengt I. Eriksson, Ola E. Dahl, et al.. (2005). Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement. The Journal of Clinical Pharmacology. 45(5). 555–565. 241 indexed citations

12.

Eriksson, Bengt I. & Ola E. Dahl. (2004). Prevention of Venous Thromboembolism Following Orthopaedic Surgery. Drugs. 64(6). 577–595. 22 indexed citations

13.

Dahl, Ola E., et al.. (2003). Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital. Acta Orthopaedica Scandinavica. 74(3). 299–304. 7 indexed citations

14.

Eriksson, Bengt I., Peter Kälebo, Ola E. Dahl, et al.. (2002). Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. The Lancet. 360(9344). 1441–1447. 205 indexed citations

15.

Hull, Russell D., Graham F. Pineo, Paul D. Stein, et al.. (2001). Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty. Annals of Internal Medicine. 1 indexed citations

16.

Dahl, Ola E.. (2000). Continuing Out-of-Hospital Prophylaxis following Major Orthopaedic Surgery: What Now?. Pathophysiology of Haemostasis and Thrombosis. 30(Suppl. 2). 101–105. 5 indexed citations

17.

Dahl, Ola E., et al.. (1999). Combined Administration of Dextran 70 and Dalteparin Does Not Increase Perioperative Blood Loss Compared to Dextran 70 Alone in Major Orthopedic Surgery. Pathophysiology of Haemostasis and Thrombosis. 29(5). 262–268. 3 indexed citations

18.

Dahl, Ola E., Trude Aspelin, Harald Arnesen, et al.. (1995). Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thrombosis Research. 80(4). 299–306. 68 indexed citations

19.

Dahl, Ola E., et al.. (1994). Toxic effects of methylmethacrylate monomer on leukocytes and endothelial cells in vitro. Acta Orthopaedica Scandinavica. 65(2). 147–153. 134 indexed citations

20.

Dahl, Ola E., et al.. (1991). 99mTc-plasmin uptake test is unreliable for diagnosing asymptomatic deep vein thrombosis after hip replacement surgery. Thrombosis Research. 62(6). 781–784. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact